Clinical trials
Histiocytosis clinical trials
Below are recruiting histiocytosis clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04665674Recruiting
Study of adults with pulmonary Langerhans cell histiocytosis
This study follows adults with a specific lung condition to better understand how it behaves over time. If you have the right diagnosis, joining could help researchers learn what to expect and how to manage it.
ParisAges 18 years+ - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Birmingham, AlabamaAges 6 months–22 years - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT02285582Recruiting
Rare blood disorder registry for histiocytic conditions
This study is a registry that collects information about people diagnosed with rare histiocytic disorders. It helps doctors better understand these conditions over time and may improve future care.
Birmingham, AlabamaAges Any age - NCT04079179RecruitingPhase 2
Cobimetinib for difficult Langerhans cell and similar disorders
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
Phoenix, ArizonaAges Any age - NCT04943198RecruitingPhase 2
Vemurafenib for hard-to-treat BRAF-mutant juvenile histiocytosis
This Phase 2 study tests the medicine vemurafenib in children with refractory juvenile histiocytosis that has a BRAF mutation. It aims to find a better schedule (timing and dose) for treatment when standard therapies haven’t worked or the disease has come back.
Warsaw, MazovianAges 1–18 - NCT05915208Recruiting
Follow-up study for people with histiocytic disorders
This study is checking in over time with people who have a histiocytic disorder. It may help doctors better understand how these conditions behave and what follow-up care works best.
Birmingham, AlabamaAges birth–89 years - NCT06197204Recruiting
Finding biomarkers in Langerhans cell histiocytosis
This study is looking for adults with Langerhans cell histiocytosis (LCH) and also for adults with certain lung conditions (like cystic lung disease or emphysema) or healthy smokers to act as controls. The goal is to find biomarkers (signs in the body) that can help doctors diagnose LCH, predict how it will progress, and see how well treatment is working.
ParisAges 18 years+ - NCT06582745RecruitingPhase 2
Trametinib for Langerhans cell histiocytosis (LCH)
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
Fort Worth, TexasAges 1–30 - NCT07022834RecruitingPhase 2
New drug combo for high-risk LCH in children
This trial tests a combination of targeted therapy (dabrafenib or trametinib) with chemotherapy (clofarabine) for children with Langerhans cell histiocytosis (LCH) that is high-risk, has come back, or is not responding to other treatments. The goal is to see if this combination can help control the disease.
Chengdu, SichuanAges birth–18 years - NCT02670707RecruitingPhase 3
Vinblastine plus prednisone versus cytarabine alone for LCH
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
Palo Alto, CaliforniaAges Up to 21 years - NCT07431060Recruiting
Modified LCH treatment with or without Luvometinib for children
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
ChengduAges birth–18 years - NCT06902792Enrolling by invitationPhase 1
Adebrelimab and trametinib for children with hard-to-treat LCH
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Wenzhou, ZhejiangAges Up to 18 years - NCT06573671Enrolling by invitation
Histiocytosis in people who inject drugs
This trial looks at a condition called PVP-histiocytosis, which can happen in people who inject drugs made from tablets containing polyvinylpyrrolidone (PVP). The goal is to study these cases to better understand the condition.
Tampere, PirkanmaaAges 18–70 - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT06742073Recruiting
Study of H syndrome and inflammation
This study looks at the link between H syndrome and related health issues, such as inflammation or histiocytosis (a type of immune cell disorder). It helps researchers learn more about how this rare genetic condition affects the body.
Petah TikvaAges Any age - NCT04773366RecruitingPhase 3
Newly diagnosed LCH children may receive cytarabine treatment
This Phase 3 trial tests a treatment plan that includes cytarabine for children newly diagnosed with LCH (a rare condition where abnormal immune-related cells form lesions). It may help control the disease while comparing outcomes with a cytarabine-based protocol.
ShanghaiAges 1 day–18 years - NCT04943211RecruitingPhase 3
PET-CT scan test to assess body inflammation in children
This Phase 3 study tests whether a special PET-CT scan tracer (fluorodeoxyglucose, or FDG) can better detect and measure a child’s suspected or confirmed histiocytosis. It also checks how safe the scan is, and how well the results match what doctors find.
Warsaw, MazovianAges 1–18 - NCT04943224RecruitingPhase 2
Trametinib dosing plan for BRAF-negative juvenile cancer
This Phase 2 trial tests whether trametinib can work in children or teens with a tumor that does not have BRAF mutations. It also studies the best timing and dose, especially after prior treatments have not worked or the disease came back.
Warsaw, MazovianAges 1–18 - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT05997602RecruitingPhase 2
Testing FCN-159 for children with LCH that returned
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
Beijing, Beijing MunicipalityAges 2–16 - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06078969RecruitingPhase 2
Prednisone pills for bone LCH in children and teens
This trial tests whether taking a steroid pill (prednisone) by mouth can help children and teenagers with bone-only LCH. It is for people who do not need surgery and can swallow pills.
Shanghai, Shanghai MunicipalityAges 2–17 - NCT06153173RecruitingPhase 2
Mirdametinib for histiocytic disorders
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
Cincinnati, OhioAges 2 years+
Hear when a new Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for histiocytosis?
- Yes. Clin2 currently lists 27 recruiting histiocytosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a histiocytosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a histiocytosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.